Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 7/20 | 0.54 |
| ▸ | RAB9A | P51151 | 5/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3752594 | 0.77 | ALDH1A1 (0.55) | P2RX7NPC1RAB9AL3MBTL1SMN1; SMN2 | |
| SCHEMBL3749017 | 0.76 | P2RX7 (0.52) | P2RX7NPC1RAB9AL3MBTL1GAA | |
| SCHEMBL3742904 | 0.76 | P2RX7 (0.54) | P2RX7EPHX2KMT2AALDH1A1HSD11B1 | |
| SCHEMBL3741865 | 0.74 | P2RX7 (0.50) | P2RX7EPHX2KMT2AALDH1A1 | |
| SCHEMBL18906066 | 0.73 | KDM4E (0.83) | KDM4ENPC1RAB9AL3MBTL1SMN1; SMN2 | |
| SCHEMBL7571375 | 0.73 | P2RX7 (1.00) | P2RX7NPC1RAB9AKMT2A | |
| SCHEMBL4578939 | 0.73 | KDM4E (0.77) | KDM4ENPC1RAB9AL3MBTL1SMN1; SMN2 | |
| SCHEMBL4578943 | 0.73 | KDM4E (0.77) | KDM4ENPC1RAB9AL3MBTL1SMN1; SMN2 | |
| SCHEMBL6127192 | 0.73 | KDM4E (0.89) | KDM4ENPC1RAB9AL3MBTL1SMN1; SMN2 | |
| SCHEMBL8657462 | 0.71 | KDM4E (0.74) | KDM4ENPC1RAB9AL3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133204-B2 | 5-membered heterocyclic amides and related compounds | H. LUNDBECK A/S (DK) | 2015-09-15 | — | — | US | disclosed |
| US-9133204-B2 | 5-membered heterocyclic amides and related compounds | H. LUNDBECK A/S (DK) | 2015-09-15 | — | — | US | disclosed |
| US-9133204-B2 | 5-membered heterocyclic amides and related compounds | H. LUNDBECK A/S (DK) | 2015-09-15 | — | — | US | disclosed |
| EP-2178865-B1 | 5-MEMBERED HETEROCYCLIC AMIDES AND RELATED COMPOUNDS | LUNDBECK H AS (DK) | 2015-08-19 | — | — | EP | disclosed |
| EP-2178865-B1 | 5-MEMBERED HETEROCYCLIC AMIDES AND RELATED COMPOUNDS | LUNDBECK H AS (DK) | 2015-08-19 | — | — | EP | disclosed |
| US-20150005293-A1 | 5-Membered Heterocyclic Amides And Related Compounds | MINDIMMUNE THERAPEUTICS, INC. | 2015-01-01 | — | — | US | disclosed |
| US-20150005293-A1 | 5-Membered Heterocyclic Amides And Related Compounds | MINDIMMUNE THERAPEUTICS, INC. | 2015-01-01 | — | — | US | disclosed |
| US-20150005293-A1 | 5-Membered Heterocyclic Amides And Related Compounds | MINDIMMUNE THERAPEUTICS, INC. | 2015-01-01 | — | — | US | disclosed |
| US-20100292236-A1 | 5-Membered Heterocyclic Amides And Related Compounds | H. LUNDBECK A/S (DK) | 2010-11-18 | — | — | US | disclosed |
| US-20100292236-A1 | 5-Membered Heterocyclic Amides And Related Compounds | H. LUNDBECK A/S (DK) | 2010-11-18 | — | — | US | disclosed |
| US-20100292236-A1 | 5-Membered Heterocyclic Amides And Related Compounds | H. LUNDBECK A/S (DK) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005293-A1 | 5-Membered Heterocyclic Amides And Related Compounds | GPR35, HCAR2, HCAR1 | KDM4E 3311/4885P2RX7 268/4885NPC1 2237/4885 |
| US-20100292236-A1 | 5-Membered Heterocyclic Amides And Related Compounds | GPR35, HCAR2, HCAR1 | KDM4E 3311/4885P2RX7 268/4885NPC1 2237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.